BACKGROUND: Visually guided laser balloon (VGLB) ablation allows for pulmonary vein isolation (PVI) under direct endoscopic control. Short- and midterm clinical outcomes are in accordance with results of radiofrequency current (RFC) ablation for the treatment of paroxysmal atrial fibrillation (PAF). OBJECTIVE: The current study sought to assess the long-term clinical outcomes of VGLB-based PVI for PAF. METHODS: A total of 90 patients [60 ± 10 years; 33 (37%) female, left atrial diameter 42 ± 4 mm] with drug-refractory PAF underwent VGLB ablation. The median duration of PAF until VGLB ablation was 36 (interquartile range 12; 84) months. Follow-up was based on outpatient clinic visits including Holter ECGs and telephone interviews. Repeat ablation due to arrhythmia recurrences was performed using RFC ablation. RESULTS: After a single VGLB procedure, 5-year freedom from arrhythmia recurrence was 51% [95% confidence interval (CI) 39-62%]. Thirty-three patients underwent repeat RFC ablation procedures, resulting in multiple procedure freedom from arrhythmia recurrence of 78% (95% CI 68-88%). Major periprocedural complications occurred in four patients (4%). CONCLUSIONS: VGLB ablation for the treatment of drug-refractory PAF is safe and results in 5-year single and multiple procedure arrhythmia-free survival of 51 and 78%, respectively.
BACKGROUND: Visually guided laser balloon (VGLB) ablation allows for pulmonary vein isolation (PVI) under direct endoscopic control. Short- and midterm clinical outcomes are in accordance with results of radiofrequency current (RFC) ablation for the treatment of paroxysmal atrial fibrillation (PAF). OBJECTIVE: The current study sought to assess the long-term clinical outcomes of VGLB-based PVI for PAF. METHODS: A total of 90 patients [60 ± 10 years; 33 (37%) female, left atrial diameter 42 ± 4 mm] with drug-refractory PAF underwent VGLB ablation. The median duration of PAF until VGLB ablation was 36 (interquartile range 12; 84) months. Follow-up was based on outpatient clinic visits including Holter ECGs and telephone interviews. Repeat ablation due to arrhythmia recurrences was performed using RFC ablation. RESULTS: After a single VGLB procedure, 5-year freedom from arrhythmia recurrence was 51% [95% confidence interval (CI) 39-62%]. Thirty-three patients underwent repeat RFC ablation procedures, resulting in multiple procedure freedom from arrhythmia recurrence of 78% (95% CI 68-88%). Major periprocedural complications occurred in four patients (4%). CONCLUSIONS: VGLB ablation for the treatment of drug-refractory PAF is safe and results in 5-year single and multiple procedure arrhythmia-free survival of 51 and 78%, respectively.
Authors: Yalçin Gökoğlan; Sanghamitra Mohanty; Mahmut F Güneş; Chintan Trivedi; Pasquale Santangeli; Carola Gianni; Issa K Asfour; Rong Bai; J David Burkhardt; Rodney Horton; Javier Sanchez; Steven Hao; Richard Hongo; Salwa Beheiry; Luigi Di Biase; Andrea Natale Journal: Circ Arrhythm Electrophysiol Date: 2016-05
Authors: Srinivas R Dukkipati; Petr Neuzil; Josef Kautzner; Jan Petru; Dan Wichterle; Jan Skoda; Robert Cihak; Petr Peichl; Antonio Dello Russo; Gemma Pelargonio; Claudio Tondo; Andrea Natale; Vivek Y Reddy Journal: Heart Rhythm Date: 2012-01-28 Impact factor: 6.343
Authors: Thomas Neumann; Maciej Wójcik; Alexander Berkowitsch; Damir Erkapic; Sergey Zaltsberg; Harald Greiss; Dimitri Pajitnev; Stefan Lehinant; Jörn Schmitt; Christian W Hamm; Heinz F Pitschner; Malte Kuniss Journal: Europace Date: 2013-02-17 Impact factor: 5.214
Authors: Srinivas R Dukkipati; Frank Cuoco; Ilana Kutinsky; Arash Aryana; Tristram D Bahnson; Dhanunjaya Lakkireddy; Ian Woollett; Ziad F Issa; Andrea Natale; Vivek Y Reddy Journal: J Am Coll Cardiol Date: 2015-09-22 Impact factor: 24.094
Authors: Karl-Heinz Kuck; Josep Brugada; Alexander Fürnkranz; Andreas Metzner; Feifan Ouyang; K R Julian Chun; Arif Elvan; Thomas Arentz; Kurt Bestehorn; Stuart J Pocock; Jean-Paul Albenque; Claudio Tondo Journal: N Engl J Med Date: 2016-04-04 Impact factor: 91.245
Authors: David J Wilber; Carlo Pappone; Petr Neuzil; Angelo De Paola; Frank Marchlinski; Andrea Natale; Laurent Macle; Emile G Daoud; Hugh Calkins; Burr Hall; Vivek Reddy; Giuseppe Augello; Matthew R Reynolds; Chandan Vinekar; Christine Y Liu; Scott M Berry; Donald A Berry Journal: JAMA Date: 2010-01-27 Impact factor: 56.272
Authors: Christian-H Heeger; Erik Wissner; Peter Wohlmuth; Shibu Mathew; Kentaro Hayashi; Christian Sohns; Bruno Reißmann; Christine Lemes; Tilman Maurer; Ardan M Saguner; Francesco Santoro; Johannes Riedl; Feifan Ouyang; Karl-Heinz Kuck; Andreas Metzner Journal: Clin Res Cardiol Date: 2016-04-16 Impact factor: 5.460
Authors: Thomas Fink; Andreas Metzner; Stephan Willems; Lars Eckardt; Hüseyin Ince; Johannes Brachmann; Stefan G Spitzer; Thomas Deneke; Claus Schmitt; Matthias Hochadel; Jochen Senges; Andreas Rillig Journal: Clin Res Cardiol Date: 2019-04-05 Impact factor: 5.460
Authors: Barbara Bellmann; Tina Lin; Peter Ruppersberg; Marit Zettwitz; Selma Guttmann; Verena Tscholl; Patrick Nagel; Mattias Roser; Ulf Landmesser; Andreas Rillig Journal: Clin Res Cardiol Date: 2018-05-09 Impact factor: 5.460
Authors: Tilman Maurer; Laura Rottner; Hisaki Makimoto; Bruno Reissmann; Christian-H Heeger; Christine Lemes; Thomas Fink; Johannes Riedl; Francesco Santoro; Peter Wohlmuth; Marius Volkmer; Shibu Mathew; Andreas Metzner; Feifan Ouyang; Karl-Heinz Kuck; Christian Sohns Journal: Clin Res Cardiol Date: 2018-05-08 Impact factor: 5.460
Authors: Laura Rottner; Barbara Bellmann; Tina Lin; Bruno Reissmann; Tobias Tönnis; Ruben Schleberger; Moritz Nies; Christiane Jungen; Leon Dinshaw; Niklas Klatt; Jannis Dickow; Paula Münkler; Christian Meyer; Andreas Metzner; Andreas Rillig Journal: Cardiol Ther Date: 2020-01-02